Recently, therapies targeting epidermal growth factor receptor (EGFR) have exhibited excellent anticancer effects with mildly adverse effects and significantly enhanced cancer radiosensitivity in preclinical and clinical studies. EGFR targeted therapies combined with radiotherapy has been regarded as a very potential strategy for treatment of some cancers of epithelial origin. Nimotuzumab is an IgG1 monoclonal antibody that blocks EGF, TGF-a and other ligands from binding to EGFR. Nimotuzumab attaches to EGFR with moderate binding affinity compared with cetuximab. In normal tissues with low EGFR density, nimotuzumab has less affinity to bind EGFR with low cytotoxicity. Current study indicates that injected mice by nimotuzumab-131I showed normal body weigh and unchange of blood cells in comparison with control animals.
- Đăng nhập để gửi ý kiến